Who is eligible for clinical trial NCT05063851?

Participants must meet the protocol's inclusion criteria for Alzheimer Disease. The stated age range is 50 Years to 65 Years. Confirm all requirements with the study coordinator.

Does clinical trial NCT05063851 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-01-12

The Use of Memantine for Prevention of Alzheimer's Disease (NCT05063851)

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: University of Virginia

🩺 Plain-English Summary (8th-Grade Level)

As the US population ages, the prevalence of dementia is increasing, and Alzheimer's Disease (AD) is the most prevalent one. Solving the Alzheimer's Disease (AD) epidemic is likely to require preventive therapy beginning many years before symptoms are expected to be evident in at-risk individuals. AD is caused by the dysfunction, loss of synapses, and eventual neuronal death, which may occur up to 25 years before clinical symptoms appear. This study, based off of pre-clinical data, seeks to assess whether it is feasible to use memantine hydrochloride for the prevention of Alzheimer's Disease.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (7 items) and avoid the listed exclusions (14 items).

Location: University of Virginia — Charlottesville, Virginia

Age range: 50 Years to 65 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Be between the age of 50 and 65 years at time of informed consent.
Have a positive family history for dementia (minimum of 1 first degree relative).
Previously known or documented heterozygote or homozygote ApoE ε4 allele.
Be able to read and write and must have adequate hearing and visual acuity to complete the psychometric tests.
Be otherwise healthy for their age group or medically stable with or without medication on the basis of physical examination, medical history, vital signs, and 12-lead ECG performed at screening or at baseline.
Have Montreal Cognitive Assessment (MOCA) score of 27 or above.
Have a creatinine clearance (CrCl), estimated using the Cockcroft-Gault formula, greater or equal to 30 mL/minute.

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
A current clinical condition or requires a medication that raises the pH of their urine.
Severe renal or hepatic impairment.
Any other abnormality that could cause a possible cognitive deficit (including, but not limited to, vascular encephalopathy or large strokes).
Contraindications for MRI (e.g., prostheses, implants, claustrophobia, pacemaker) or PET imaging.
Neurodegenerative disorder known to cause neurocognitive decline
Relevant history of or current neurological disease other than preclinical AD, which may make interpretation of possible new neurological signs or symptoms difficult.
Clinically significant and active pulmonary, gastrointestinal, renal, hepatic, endocrine, or cardiovascular system disease
Ongoing cancer treatment
Clinically significant and active psychiatric disorder
Use of an investigational medical device within 3 months before the planned start of study.
Current participation in an interventional study with an investigational drug component.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

University of Virginia — Charlottesville, Virginia

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Alzheimer Disease

Automated, Assistive, Non-Contact Sleep Quality Monitor for Individuals With Alzheimer's Disease — Indianapolis, Indiana
Low-Intensity Focused Ultrasound (LIFU) Neuromodulation — Morgantown, West Virginia
2-Hydroxybenzylamine (2-HOBA) Study in Early Alzheimer's Patients — Nashville, Tennessee
[18F]PI-2620 Phase 3 Histopathological Study — Phoenix, Arizona
A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease — Irvine, California

Explore by condition: All Alzheimer Disease clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Review the official NIH record below to find the coordinating site.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗